Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter favorable biodistribution profile in non-human primates using a clinically validated editing strategy
You might also be interested in reading Biggest Movers: LTC Moves to 6-Month High, SOL up Nearly 20%.